/EIN News/ — SAN DIEGO, Sept. 02, 2020 (GLOBE NEWSWIRE) — via NEWMEDIAWIRE — Medical Marijuana, Inc. (OTC: MJNA) (the “Company”), the first-ever publicly traded cannabis company in the United States that launched the world’s first-ever cannabis-derived nutraceutical products, brands and supply chain, announced today that its subsidiary Kannaway® has begun recruiting cannabidiol (CBD) users to participate in the ValidCare CBD safety study. The nationwide observational study is using its products to measure the potential effects on the liver of orally consumed, hemp-derived CBD products in healthy adults. Participants will provide real-time feedback via ValidCare’s Virtual Study™ platform and supply blood samples for evaluation as part of the study.
“Since day one, we have been dedicated to providing our consumers with safe, consistent products they can trust,” said Medical Marijuana, Inc. CEO Dr. Stuart Titus. “This study helps us further that commitment and lets us take part in an industry effort to provide further evidence that CBD holds many wellness benefits without harmful side effects.”
The IRB-approved study, which was designed to respond to the FDA’s many requests for science-based data, is being conducted by ValidCare and qualifies as a national clinical trial. Kannaway® is one of 13 industry-leading companies to participate and help the FDA determine the regulatory path for hemp-derived CBD products. Each company is responsible for providing lot-specific product information for the study and recruiting a target of 100 consumers to participate. Upon completion of the study, Kannaway will receive safety data pertaining to those specific participants. Consumers are screened to ensure they meet study criteria before they are approved and enrolled. Participants will use Kannaway hemp-derived CBD or CBD isolate products for 30 consecutive days and provide a blood sample. Over 1,000 consumers have expressed interest in being part of the study.
“It’s encouraging to see the CBD industry working together to further CBD research,” said Kannaway® CEO Blake Schroeder. “We invest greatly in scientific research, including internal and external independent studies such as ValidCare’s because it is essential to gaining consumer trust.”
Results of the study will be shared with the FDA and are expected to be published in a peer-reviewed journal in early 2021.
To learn more about the study please visit https://validcare.com/validcare-national-cbd-liver-function-study/.
ValidCare, LLC provides contract research outsourcing (CRO) and virtual research solutions for life sciences and consumer packaged goods industries. ValidCare’s proprietary platform…